AtaiBeckley Stockholders Approve Eli Lilly Merger; Closing Expected September 11
ATAI has more than doubled off its 52-week low of $3.265 on elevated volume (8.5× avg).
Summary
AtaiBeckley stockholders voted overwhelmingly to approve the Eli Lilly acquisition, with closing expected September 11, 2026.
Key Events · M&A and Partnerships · ATAI
-
Merger Proposal Approved
Stockholders approved the Eli Lilly merger with 237,762,253 votes for (97.7% of votes cast), 5,033,755 against, and 555,549 abstentions.
-
Closing Date Set
AtaiBeckley expects the merger to be consummated on September 11, 2026, subject to satisfaction or waiver of remaining closing conditions.
-
Strong Stockholder Turnout
243,351,557 shares (65.6% of 370,864,669 outstanding) were represented at the special meeting, constituting a quorum.
-
Deal Terms Recap
The merger agreement, dated July 15, 2026, provides for $6.75 per share in cash plus up to $2.50 per share in contingent value rights.
Analysis · ATAI · Life Sciences
Today's special meeting delivered a decisive outcome: 97.7% of votes cast favored the Eli Lilly acquisition, clearing the final major hurdle before the $6.75 per share cash deal closes, now expected on September 11, 2026. With 65.6% of outstanding shares represented, the approval removes the last meaningful uncertainty around the transaction. The stock currently trades at $7.32, above the $6.75 cash consideration, reflecting the market's expectation that the deal will close as planned.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATAI was trading at $7.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $3.27 to $7.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.